New drug cocktail targets tough cancers in kids
NCT ID NCT02389309
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This early-phase trial tests the safety and best dose of a three-drug combination (dasatinib, temsirolimus, and cyclophosphamide) in children and young adults (ages 1 to 21) with advanced solid tumors that have come back or not responded to standard treatments. The goal is to find the highest safe dose and see how well the drugs work together to stop tumor growth. The study is not yet recruiting and involves 14 participants at MD Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.